Hormonal
GLP-1 receptor agonists (GLP-1RAs) exert immunoregulatory effects by promoting the polarization of macrophages and microglia from a pro-inflammatory M1 phenotype to an anti-inflammatory M2 phenotype, thereby reducing neuroinflammation and systemic inflammatory markers.
If you are using a GLP-1RA (like semaglutide or liraglutide) for diabetes or weight loss, understand that it may also be helping to lower systemic inflammation by shifting your immune cells toward a less inflammatory state. This is not just a side effect but a direct mechanism of action on your immune system.
Activation of GLP-1R signaling promotes M2-like macrophage phenotype while inhibiting M1-like macrophages across various models... GLP-1RAs, such as exendin-4 and liraglutide, can reduce neuroinflammation caused by microglia by encouraging a conversion from the pro-inflammatory M1 subtype towards the anti-inflammatory M2 phenotype.
Why this rating
The evidence is largely derived from in vitro studies, preclinical animal models, and mechanistic reviews, with limited direct clinical trial data for autoimmune outcomes presented in this specific text.
Source
Roles of glucagon-like peptide 1 receptor agonists in immune cell biology and autoimmune/autoinflammatory diseases
Sihui Deng et al. · Cell & Bioscience · 2025
DOI 10.1186/s13578-025-01486-8
More from this paper
- GLP-1RAs modulate T cell differentiation by reducing the proportion of pro-inflammatory Th17 cells and increasing regulatory T cells (Tregs), thereby improving immune tolerance and reducing inflammation in conditions like psoriasis and colitis.Moderate
- GLP-1RAs reduce innate allergic inflammation and eosinophilia by inhibiting the activity of Group 2 Innate Lymphoid Cells (ILC2s) and reducing the production of type 2 cytokines (IL-5, IL-13).Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →